Evolving horizons in renal angiomyolipoma: two decades of management strategies and clinical perspectives in a single institutional study

dc.authorid0000-0002-2803-6481
dc.authorid0000-0002-2785-0406
dc.authorid0000-0002-3386-971X
dc.authorid0000-0002-4647-4864
dc.authorid0000-0001-5436-1803
dc.authorid0000-0002-5822-7799
dc.contributor.authorKeles, Ahmet
dc.contributor.authorIplikci, Ayberk
dc.contributor.authorArıkan, Özgür
dc.contributor.authorCulpan, Meftun
dc.contributor.authorBaydili, Kursad Nuri
dc.contributor.authorKeser, Ferhat
dc.contributor.authorYıldırım, Asıf
dc.date.accessioned2025-05-10T19:45:22Z
dc.date.issued2024
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractObjective To assess various management options for renal angiomyolipoma (AML) to guide clinical practice. Methods A single center retrospectively reviewed an AML series from 2002 to 2022. The image reports and chart reviews of patients who received two abdominal scans at least 6 months between the first and last scans were assessed. Results A total of 203 patients with 209 tumors were identified and followed up for a median of 42.6 months. Active surveillance (AS) was the most frequently selected option (70.9% of cases). Interventions were required for 59 AMLs, of which 20 were treated with embolization, 29 with partial nephrectomy, 9 with radical nephrectomy, and 1 with radiofrequency (RF) ablation. The median size of the lesions at intervention was 5 cm. The average growth rate of the lesions was 0.12 cm/year, and there was a significant difference in the average growth rate of lesions <= 4 cm and those >4 cm (0.11 vs. 0.24 cm/year; p = 0.0046). Conclusion This series on AMLs confirms that lesions >4 cm do not require early intervention based on size alone. Appropriately selected cases of renal AML can be managed by AS.
dc.identifier.doi10.1080/13685538.2024.2346308
dc.identifier.issn1368-5538
dc.identifier.issn1473-0790
dc.identifier.issue1
dc.identifier.pmid38709235
dc.identifier.scopus2-s2.0-85192138793
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1080/13685538.2024.2346308
dc.identifier.urihttps://hdl.handle.net/20.500.14730/11242
dc.identifier.volume27
dc.identifier.wosWOS:001214851400001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofAging Male
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectAngiomyolipoma
dc.subjectactive surveillance
dc.subjectembolization
dc.subjectnephrectomy
dc.subjectnephron-sparing surgery
dc.titleEvolving horizons in renal angiomyolipoma: two decades of management strategies and clinical perspectives in a single institutional study
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
11242.pdf
Boyut:
670.77 KB
Biçim:
Adobe Portable Document Format